Pharmaron Beijing Co., Ltd. (SZSE:300759) entered into equity transfer agreement to acquire 21.6874% stake in Pharmaron (Chengdu) Clinical Services Co., Ltd from Mr. Yu Wu and Mr. Li Xianghao for RMB 506.79 million on October 27, 2022. Under the agreement, 70% of the Equity Transfer Agreement Consideration shall be paid to Mr. Yu Wu and Mr. Li Xianghao within ten (10) working days and the remaining 30% of the Equity Transfer Agreement Consideration shall be paid to Mr. Yu Wu and Mr. Li Xianghao before December 31, 2022.